SYDNEY, Australia; 2 August 2006: Australia’s safety syringe company, Ritract Limited (ASX: RTL) today announced the appointment of former ResMed executive Bill Nicklin as Chief Executive Officer to lead the company’s expansion into major global markets.
Mr Nicklin brings to Ritract more than 16 years experience in the global commercialisation and
manufacturing of medical devices. His speciality areas include product development, global
manufacturing, strategic planning and international business development.
He was one of the first employees of Australian-based medical device manufacturer ResMed Limited
where he laid the foundations for the company’s successful global manufacturing operations.
His most recent position was Vice President Quality Assurance for Australia. He takes up his new role on the 21 August 2006.
Mr Nicklin takes over from Rupert Northcott who is unable to renew his three-year contract in October for
personal reasons. Mr Northcott remains on the Board and will work with Mr Nicklin to ensure a smooth
Ritract Chairman Mr Michael Boyd praised Mr Northcott’s contribution. “Rupert has taken the company from a great idea to a great manufactured product. He has been instrumental in providing strategic
leadership, putting a strong collaborative team in place, laying the foundations for our global manufacturing capability and for securing pending distribution and marketing agreements in key markets.
Rupert leaves Ritract well-positioned for future revenue growth as a successful global business.”
Mr Boyd said Mr Nicklin’s appointment came at a critical time in the commercial development of the company. “Bill will build on the momentum created to help us secure a major leadership position in the rapidly evolving global retractable syringe markets.
“We are pleased Ritract has attracted such a widely experienced and well respected medical device
executive to lead the team in our international efforts to commercialise the product range.
“Bill’s experience and skills will help take the Company to the next level where world-standard large scale manufacturing and quality assurance systems and processes will support market acceptance.
“The Board thanks Mr Northcott for his valuable contribution to the company and welcomes his ongoing
responsibility as a non-executive Director,” Mr Boyd said.
Bill has 32 years experience gained within the industrial/engineering, manufacturing and medical device industry sectors and has held a variety of roles including, Production Engineer, GM of Manufacturing, Director of Manufacturing, VP Manufacturing, VP European Systems Development and VP QA Australia.
He began his career in plastic molding with TUTA Laboratories in 1974 before moving to Hanimex to work
in new product development and as General Manager of Manufacturing and Director of Manufacturing when the company became Valuca Pty Ltd.
He joined ResMed in 1990 as Production Manager and became VP of Manufacturing in 1995. As VP of
Manufacturing, Bill’s key responsibilities were to manage the full supply chain and logistics and ensure
the full profitability of the manufacturing process. He was appointed to the board of the local ResMed
business, ResMed Ltd.
In 2004 he played a significant role in the merging of two German businesses for the group in Europe as VP European Systems Development reporting to the COO of Europe. In 2005 he assisted in the acquisition of a French Ventilation business and managed the business through to 2006. He moved back to Australia in 2006 to take up the role of VP QA with ResMed.
Ritract Limited’s patented unique technology is designed to meet world demand for innovative, safety injection solutions in global health markets. Ritract's immediate markets are health care workers at the front line of the international medical community, with the primary aim being to protect them from needle stick injury. The company’s vision is to help create a safer world by replacing every non-safety needle and syringe with Ritract safety technology.